Carolina Martínez‐Laperche

ORCID: 0000-0001-6802-3485
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hematopoietic Stem Cell Transplantation
  • Acute Myeloid Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • CAR-T cell therapy research
  • Cancer Genomics and Diagnostics
  • Chronic Myeloid Leukemia Treatments
  • T-cell and B-cell Immunology
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Cytomegalovirus and herpesvirus research
  • SARS-CoV-2 and COVID-19 Research
  • Immunodeficiency and Autoimmune Disorders
  • SARS-CoV-2 detection and testing
  • Renal Transplantation Outcomes and Treatments
  • Viral-associated cancers and disorders
  • Transplantation: Methods and Outcomes
  • COVID-19 Clinical Research Studies
  • Renal and related cancers
  • Polyomavirus and related diseases
  • Mesenchymal stem cell research
  • Cancer-related Molecular Pathways
  • Advanced Breast Cancer Therapies
  • Respiratory viral infections research

Hospital General Universitario Gregorio Marañón
2016-2025

Universidad Carlos III de Madrid
2024

Universidad Complutense de Madrid
2021

Instituto de Biomedicina de Valencia
2021

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
2021

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
2021

Institute for Integrative Systems Biology
2021

Universitat de València
2021

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
2021

John Wiley & Sons (United States)
2018

This article has been corrected. The original version (PDF) is appended to this as a Supplement. Background: multifactorial mechanisms associated with radical reductions in HIV-1 reservoirs after allogeneic hematopoietic stem cell transplant (allo-HSCT), including case of HIV cure, are not fully understood. Objective: To investigate the mechanism eradication allo-HSCT. Design: Nested series within IciStem observational cohort. Setting: Multicenter European study. Participants: 6...

10.7326/m18-0759 article EN Annals of Internal Medicine 2018-10-16

Abstract Chimeric antigen receptor (CAR) T cell–related HLH/MAS is an unusual manifestation of severe cytokine release syndrome (CRS) with poor prognosis and a challenging diagnosis. The establishment specific diagnosis criteria essential, the combination several techniques for CAR T‐cell follow‐up, allows more precise management this complication.

10.1002/ccr3.5209 article EN Clinical Case Reports 2022-01-01

Relapse remains the main cause of treatment failure in patients with acute myelogeous leukemia (AML) after allogeneic hemopoietic stem cell transplantation (SCT). The Wilms' tumor 1 gene (WT1) is reportedly overexpressed >90% AML and thus can be useful for minimal residual disease (MRD) monitoring. aim this study was to evaluate usefulness WT1 expression as a relapse predictor marker SCT compare it flow cytometry (FC) chimerism studies. assessed retrospectively using quantitative RT-PCR bone...

10.1016/j.bbmt.2012.01.012 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2012-01-25

Abstract Allogeneic stem cell transplantation (allo‐ SCT ) has become the treatment of choice in patients with intermediate‐risk and high‐risk acute myeloid leukemia ( AML ). The quality response to treatment, assessed terms detection minimal residual disease MRD ), been consistently associated prognosis clinical outcome . aim present study was evaluate prognostic impact analyzing bone marrow using 4‐color multiparametric flow cytometry MFC 29 before after allo‐ Eighteen who were shown be...

10.1111/ejh.12336 article EN European Journal Of Haematology 2014-04-05

We aimed at assessing the clinical significance of levels acute lymphoblastic leukemia (ALL) cells in samples cerebrospinal fluid (CSF) during therapy. studied 990 CSF from 108 patients, time diagnosis (108) and each intrathecal therapy (882). The proportions leukemic were assessed by flow cytometry (FCM). Patients with central nervous system (CNS) involvement (FCM+) showed predominantly a T-ALL, higher percentages known negative prognostic factors: high risk group, white blood cell counts,...

10.1002/ajh.23407 article EN American Journal of Hematology 2013-02-08

A successful Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant, B.1.1.7, has recently been reported in the UK, causing global alarm. Most likely, new variant emerged a persistently infected patient, justifying special focus on these cases. Our aim this study was to explore certain clinical profiles involving severe immunosuppression that may help explain prolonged persistence of viable viruses. We present three severely immunosuppressed cases (A, B, and C) with history...

10.3390/biomedicines9070808 article EN cc-by Biomedicines 2021-07-13

Chimeric antigen receptor T-cells (CAR-T) has emerged as a promising therapy, over 60% of patients fail to sustain long-term response. The underlying factors that leads the effectiveness this therapy are not completely understood, CAR-T cell persistence and monitoring seems be pivotal for ensuring successful Various methods such multiparametric flow cytometry (MFC) or quantitative PCR (qPCR) have been applied. Our objective is develop digital (dPCR) assays detection quantification cells,...

10.1016/j.jtct.2023.12.672 article EN cc-by-nc-nd Transplantation and Cellular Therapy 2024-01-05

Posttransplant cyclophosphamide (PTCy) effectively prevents graft-versus-host disease (GVHD) after HLA-haploidentical hematopoietic stem cell transplantation (HSCT). The use of PTCy in HLA-identical HSCT is less explored. We conducted a retrospective study 107 consecutive patients undergoing an sibling (10/10) 2 centers Spain, 50 with GVHD prophylaxis methotrexate-cyclosporin A (MTX-CsA) and 57 using PTCy-based regimen additional immunosuppression. Graft source was unmanipulated mobilized...

10.1182/bloodadvances.2019000236 article EN cc-by-nc-nd Blood Advances 2019-11-05

Chimerism refers to the relative proportion of donor and recipient DNA after hematopoietic stem cell transplantation (HSCT) its quantitative follow-up is great clinical utility in this setting. PCR short tandem repeats (STR-PCR) constitutes gold standard method for chimerism quantification, although more sensitive techniques (such as qPCR) have recently arisen. We compared sensitivity quantification capacity both patient samples artificial mixtures demonstrated adequate performance methods,...

10.3390/genes11090993 article EN Genes 2020-08-25

EZH2 is mutated in nearly 25% of follicular lymphoma (FL) cases. Little known about how affects patients' response to therapy. In this context, the aim study was retrospectively analyze frequency mutations at diagnosis tissue and ctDNA patients with FL assess outcomes after receiving immunochemotherapy, depending on mutation status. Among 154 included study, 27% had (46% high-grade 26% low-grade FL). Of samples, identified 44% not any patient unmutated tissue.Unmutated who received R-CHOP...

10.1186/s12885-022-10070-z article EN cc-by BMC Cancer 2022-09-14
Šárka Pavlová Jitka Malčíková Lenka Radová Silvia Bonfiglio Jack B. Cowland and 94 more Christian Brieghel Mette Klarskov Andersen Maria Karypidou Bella Biderman Michael Doubek Grégory Lazarian Inmaculada Rapado Matthijs Vynck Naomi Porret Martin Andres Dina Rosenberg Dvora Sahar Carolina Martínez‐Laperche Ismael Buño Andrew Hindley D. Donaldson Julio Bravo Sánchez José A. García‐Marco Alicia Serrano‐Alcalá Blanca Ferrer Lores Concepción Fernández‐Rodríguez Beatríz Bellosillo Stephan Stilgenbauer Eugen Tausch Hero Nikdin Fiona Quinn Emer Atkinson Lisette van de Corput Cafer Yildiz Cristina Bilbao Yanira Florido Christian Thiede Caroline Schuster Anastazja Stoj Sylwia Czekalska Anastasia Chatzidimitriou Stamatia Laidou Audrey Bidet Charles Dussiau Friedel Nollet Giovanna Piras Maria Monne Svetlana Smirnova Eugene Nikitin Ivan Sloma Alexis Claudel Laëtitia Largeaud Loïc Ysebaert Peter J.M. Valk Amy Christian Renata Walewska David Oscier Marta Sebastião María Gomes da Silva Piero Galieni Mario Angelini Davide Rossi Valeria Spina Sónia Matos Vânia Martins Tomasz Stokłosa Monika Pępek Panagiotis Baliakas R. Andreu Irene Luna Tiina Kahre Ülle Murumets Tereza Pikousova Terézia Kurucová Sophie Laird Daniel Ward Miguel Alcoceba Ana Balanzategui Lydia Scarfò Francesca Gandini Ettore Zapparoli Adoración Blanco Pau Abrisqueta Ana E. Rodríguez‐Vicente Rocí­o Benito Clotilde Bravetti Frédéric Davi Paula Gameiro Joaquin Martinez‐Lopez Bárbara Tazón‐Vega Fanny Baran‐Marszak Zadie Davis Mark Catherwood Andrey Sudarikov Richard Rosenquist Carsten Utoft Niemann Κώστας Σταματόπουλος Paolo Ghia Šárka Posp̂íšilová

Abstract In chronic lymphocytic leukemia, the reliability of next‐generation sequencing (NGS) to detect TP53 variants ≤10% allelic frequency (low‐VAF) is debated. We tested ability 23 such in 41 different laboratories using their NGS method choice. The sensitivity was 85.6%, 94.5%, and 94.8% at 1%, 2%, 3% VAF cut‐off, respectively. While only one false positive (FP) result reported >2% VAF, it more challenging distinguish true <2% from background noise (37 FPs by 9 laboratories)....

10.1002/hem3.70065 article EN cc-by-nc-nd HemaSphere 2025-01-01

Molecular diagnosis of myeloid neoplasms (MN) is based on the detection multiple genetic alterations using various techniques. Next-generation sequencing (NGS) has been proved as a useful method for analyzing many genes simultaneously. In this context, we analyzed diagnostic samples from 121 patients affected by MN and ten relapse subset acute leukemia two enrichment-capture NGS gene panels. Pathogenicity classification variants was enhanced development application custom onco-hematology...

10.3390/cancers11091364 article EN Cancers 2019-09-13

// Gonzalo Blanco 1, 2, 3 , Anna Puiggros 2 Panagiotis Baliakas 4 Anastasia Athanasiadou 5 MªDolores García-Malo 6 Rosa Collado 7 Aliki Xochelli 4, 8 María Rodríguez-Rivera Margarita Ortega 9 Mª José Calasanz 10 Elisa Luño 11 MªTeresa Vargas 12 Javier Grau 13 Carolina Martínez-Laperche 14 Alberto Valiente 15 Cervera 16 Achilles Anagnostopoulos Eva Gimeno 17 Eugènia Abella Evangelia Stalika Jesús Hernández-Rivas 18...

10.18632/oncotarget.13106 article EN Oncotarget 2016-11-04

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for patients with hematologic malignances. Haploidentical HSCT (Haplo-HSCT) an alternative option who do not have HLA-matched donor. The use of post-transplantation high dose cyclophosphamide (PT-Cy) commonly employed graft-versus-host disease (GVHD) prophylaxis in haplo-HSCT. Cyclophosphamide (Cy) alkylating agent antineoplastic and immunosuppressive activity, whose bioactivation requires the activity...

10.3389/fimmu.2022.1002959 article EN cc-by Frontiers in Immunology 2022-09-23

Introduction: Although a number of patients with HIV infection and hematological disease have successfully undergone allogeneic hematopoietic stem-cell transplantation (HSCT), short long-term outcomes remain not well known. We report the largest Spanish experience treating HIV-infected adult high-risk malignancies HSCT. Methods: retrospectively reviewed 22 HIV-positive who received HSCT in five centers Spain. Results: A total were transplanted between 1999 2018. Median age was 44 years. With...

10.1097/qad.0000000000002209 article EN AIDS 2019-04-01

Centers for Disease Control and Prevention guidelines consider SARS-CoV-2 reinfection when sequential COVID-19 episodes occur >90 days apart. However, genomic diversity acquired over recent waves could mean previous infection provides insufficient cross-protection. We used analysis to assess the percentage of early reinfections in a sample 26 patients with 2 separated by 20-45 days. Among sampled patients, 11 (42%) had involving different variants or subvariants. Another 4 cases were...

10.3201/eid2906.221696 article EN cc-by Emerging infectious diseases 2023-05-16

Background CART therapy has produced a paradigm shift in the treatment of relapsing FL patients. Strategies to optimize disease surveillance after these therapies are increasingly necessary. This study explores potential value ctDNA monitoring with an innovative signature personalized trackable mutations. Method Eleven patients treated anti-CD19 CAR T-cell were included. One did not respond and was excluded. Genomic profiling performed before starting lymphodepleting chemotherapy identify...

10.3389/fimmu.2023.1188818 article EN cc-by Frontiers in Immunology 2023-06-05

Abstract Background SARS-CoV-2 recombinants involving the divergent Delta and Omicron lineages have been described, one of them, “Kraken” (XBB.1.5), has recently a matter concern. Recombination requires coexistence two strains in same individual. Only limited number studies focused on identification co-infections are restricted to Delta/Omicron lineages. Methods We performed systematic throughout pandemic (7609 different patients sequenced), not biassed towards involvement highly Through...

10.1186/s13073-023-01198-z article EN cc-by Genome Medicine 2023-07-24
Coming Soon ...